Skip to main navigation
Skip to search
Skip to main content
Sort by
INIS
anticoagulants
33%
atherosclerosis
9%
comparative evaluations
12%
conferences
10%
coronaries
21%
coronaviruses
13%
data
9%
diseases
34%
emergencies
8%
fibrinogen
8%
fibrinolysis
8%
heparin
17%
inflammation
12%
interventions
21%
ischemia
10%
kidneys
12%
laboratories
14%
management
14%
molecular weight
8%
monitoring
11%
patients
100%
plasminogen
7%
prothrombin
11%
recommendations
8%
risks
33%
testing
7%
therapy
44%
thrombin
10%
thrombosis
14%
vitamin k
8%
Keyphrases
Activated Partial Thromboplastin Time (aPTT)
7%
Activated Prothrombin Complex Concentrates (aPCC)
10%
Anticoagulation
7%
Antithrombotic Therapy
7%
Bleeding
8%
Bleeding Risk
7%
Clinical High Risk
15%
Clopidogrel
6%
Coronavirus Disease (COVID)
16%
COVID-19
14%
Direct Oral Anticoagulants
21%
EXTEM
7%
Factor Xa Inhibitors
7%
Fibrinogen
8%
Fibrinolysis
7%
Hemostasis
9%
Inflammation
6%
Intensive Care
16%
Low Molecular Weight Heparin
6%
Maastricht
21%
Optimal Management
6%
Percutaneous Coronary Intervention
14%
Peripheral Arterial Disease
8%
Rotational Thromboelastometry (ROTEM)
20%
Thrombin Generation
6%
Thrombosis
6%
Triple Antithrombotic Therapy
10%
Unfractionated Heparin
10%
Venous Thromboembolism
7%
Vitamin K Antagonists
7%
Medicine and Dentistry
Acetylsalicylic Acid
7%
Anticoagulation
8%
Antithrombotic
13%
Antithrombotic Therapy
16%
Arteriosclerosis Obliterans
7%
Atherosclerosis
7%
Bleeding
9%
Blood Clotting
9%
Blood Clotting Factor 10a Inhibitor
6%
Blood Stasis
10%
Cardiovascular Disease
6%
COVID-19
20%
Direct Oral Anticoagulant
20%
Diseases
5%
Fibrinogen
6%
Fibrinolysis
7%
Function Test
5%
Heparin
6%
Inflammation
10%
Intensive Care
15%
Laboratory Test
6%
Percutaneous Coronary Intervention
10%
Platelet
5%
Prothrombin Complex
10%
Pulmonary Embolism
5%
Thrombocyte Function
5%
Thromboelastometry
14%
Thromboembolism
10%
Thrombosis
17%
Venous Thromboembolism
6%